SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E, Garmendia I, Lozano T, Serrano D, Senent Y, Redrado M, Villalba M, De Andrea CE, Exposito F, Ajona D, Ortiz-Espinosa S, Remirez A, Bertolo C, Sainz C, Garcia-Pedrero J, Pio R, Lasarte J, Agorreta J, Montuenga LM, Calvo A.
Redin E, et al. Among authors: serrano d.
J Immunother Cancer. 2021 Mar;9(3):e001496. doi: 10.1136/jitc-2020-001496.
J Immunother Cancer. 2021.
PMID: 33658304
Free PMC article.